Psychedelic-assisted psychotherapy research is being expanded to examine its effectiveness for people with a variety of diagnostic presentations.  Is there a one-size-fits-all model, or do we need to consider expanding our models?  This may be going against a trend to find forms of treatment that are brief and simpler in application.   The presentation considers whether we may learn something from instances where our applications of psychedelic medicines in research settings have not been helpful.  This may also have relevance for our models of training for therapists working in this field.


Renee Harvey is a highly experienced clinical psychologist who relocated from the UK to Australia to develop training in psychedelic-assisted psychotherapy (PAP).  She has many years of experience as a lecturer, trainer, clinician and service developer within the mental health field. Her ideas on PAP training are featured in a recently published book chapter (Harvey, 2021) and in various talks and podcasts. 

Prior to relocation, Renee was an Honorary Research Fellow and assistant guide in the Imperial College London trial researching psilocybin for treatment-resistant depression. She also facilitated the development of psychedelic interest groups and established and ran a psychedelic Integration Circle in Brighton. 

Renee is currently assisting as a therapist on the psilocybin trials at St Vincent’s Hospital, Melbourne, aimed at the alleviation of depression and anxiety associated with life-threatening illness.  She is also on the Clinical Advisory Board of Reset Mind Sciences, providing therapist training for their psychedelic research program.  She also has a private practice in Melbourne with an emphasis on providing psychedelic integration.

Written by